TL;DR
Cagrilintide is a long-acting amylin analog being studied for weight management. It is not a GLP-1 drug, although researchers have tested it with semaglutide under the name CagriSema. As reviewed on September 7, 2026, our sources do not establish an FDA-approved cagrilintide product or standard patient dose.
What is cagrilintide?
Cagrilintide is an investigational, long-acting amylin analog. Researchers are studying it alone and with other medicines for weight management and metabolic conditions.
CagriSema is the research name commonly used when cagrilintide is administered with semaglutide. Evidence about this combination does not establish cagrilintide as an approved medicine or support unsupervised use.
What natural amylin does
The pancreas releases amylin alongside insulin after food intake. Amylin contributes to signals associated with fullness, food intake and stomach emptying.
Appetite suppression is not a complete measure of health. Weight-management care also needs to account for nutrition, hydration, strength, medical history and whether treatment remains tolerable over time.
How cagrilintide changes the amylin signal
Cagrilintide is designed to provide longer-lasting amylin-like activity than the body’s natural signal. Researchers must still establish its benefits, risks and appropriate uses through controlled trials.
A plausible mechanism does not prove that a medicine is effective or suitable for a particular patient.
Is cagrilintide FDA-approved?
Status reviewed September 7, 2026: Our sources do not establish an FDA-approved cagrilintide product, indication, label or routine prescription dose. We recommend confirming the latest status through Drugs@FDA and current manufacturer records.
Cagrilintide and CagriSema also require separate regulatory checks. A completed Phase 3 trial or positive study result is not the same as FDA approval.
What must happen before routine prescribing
The FDA review process generally includes:
- Clinical evidence covering efficacy and safety
- A formal marketing application
- Review of study methods and results
- Review of manufacturing quality
- Approved indications, dosing, warnings and labeling
- Continued safety monitoring after approval
Source 2 describes RENEW 1 as a Phase 3 cagrilintide obesity trial lasting 64 weeks. It was listed as active but not recruiting. That status shows ongoing clinical development, not regulatory approval.
Why there is no standard patient dose before a label
Research protocols specify doses for closely monitored study participants. They do not create general starting doses, maintenance schedules, missed-dose instructions or combination plans.
We do not recommend converting a trial schedule into personal dosing instructions.
Cagrilintide trial results: how to read the weight-loss numbers
A useful trial summary identifies the population, study phase, treatment arms, duration, endpoint, analysis method and discontinuations. The supplied sources support the following limited overview:
| Study | Population and design | Duration | What the supplied source reports |
|---|---|---|---|
| REDEFINE 1 | Phase 3a; adults without diabetes who had obesity, or overweight with a related condition | 68 weeks | Double-blind trial comparing CagriSema, cagrilintide, semaglutide and placebo |
| REDEFINE 2 | Adults with overweight or obesity and type 2 diabetes | Not stated in the excerpt | Cagrilintide–semaglutide reduced weight and improved glycemic control in the studied population |
| RENEW 1 | Phase 3 cagrilintide obesity study for adults | 64 weeks | Once-weekly subcutaneous treatment studied under a controlled protocol |
Source 1 says REDEFINE 1 used a treatment-policy estimand under an intention-to-treat framework. This approach evaluates outcomes according to initial treatment assignment under prespecified rules, including certain events after treatment changes or discontinuation.
Cagrilintide alone in adults with overweight or obesity
Early research examined cagrilintide in adults with overweight or obesity. The supplied excerpts describe the results as promising but do not provide enough numerical detail for us to present a complete efficacy or safety table.
These studies also cannot show what would happen if someone independently added cagrilintide to another prescription.
Cagrilintide with semaglutide in obesity and type 2 diabetes
REDEFINE 1 studied adults without diabetes, while REDEFINE 2 involved adults with type 2 diabetes. Results from these populations are not interchangeable.
Diabetes status, other medicines, baseline health and study methods can all affect weight, glucose and safety outcomes.
Why one trial percentage cannot name a winner
Results from separate trials may differ because of:
- Participant characteristics
- Diabetes status
- Treatment duration
- Dose-escalation methods
- Adherence and discontinuation
- Missing-data rules
- Lifestyle support
- Statistical methods
We compare those design features before comparing headline percentages.
Cagrilintide vs semaglutide vs tirzepatide
These medicines do not belong to the same drug class.
| Medicine | Drug class | Regulatory position |
|---|---|---|
| Cagrilintide | Long-acting amylin analog | Investigational based on the reviewed sources |
| Semaglutide | GLP-1 receptor agonist | Available in FDA-approved, product-specific forms |
| Tirzepatide | GIP and GLP-1 receptor agonist | Available in FDA-approved, product-specific forms |
Cagrilintide versus semaglutide
Cagrilintide targets the amylin pathway, while semaglutide targets the GLP-1 receptor. Their different mechanisms support combination research but do not prove that one is better.
A fair comparison requires direct evidence in similar patients using the same methods.
Cagrilintide versus tirzepatide
Tirzepatide acts through GIP and GLP-1 receptors rather than the amylin pathway. That distinction alone does not establish greater weight loss, better tolerability or lower risk for any medicine.
Cagrilintide plus semaglutide
Cagrilintide and semaglutide have been coadministered in clinical trials. This research does not provide general permission to combine separately obtained products.
A licensed prescriber should review any proposed change to an approved treatment plan.
Cagrilintide side effects, exclusions, and open safety questions
The supplied excerpts do not provide a complete adverse-event table. Full trial reports are needed to assess event types, frequency, severity, timing and treatment discontinuations.
Cagrilintide also has no final FDA-approved contraindication, warning or interaction list in the sources we reviewed. Severe or persistent symptoms after exposure to any unapproved product require prompt medical care.
Who was excluded from trials
Source 2 reports that RENEW 1 excluded people taking weight-management drugs or amylin-based compounds and identifies diabetes as a disqualifier.
Exclusions vary between protocols. They may reflect safety concerns, study design or attempts to reduce confounding; they do not automatically prove harm in every excluded group.
Risks researchers are tracking
Investigators monitor adverse events, treatment discontinuations and changes in relevant health measures. The exact monitoring plan depends on the protocol and population.
We also look for information about nutrition, hydration and body composition rather than treating weight change as the only meaningful outcome.
Why more appetite suppression is not always better
Very low food intake can make it harder to meet nutritional and hydration needs. A sound benefit-risk assessment considers tolerability, strength, daily function and the likelihood that treatment can be sustained.
Cagrilintide dosage charts: trial protocols are not prescriptions
Our reviewed sources do not establish a standard cagrilintide patient dose. Only an approved label could provide product-specific prescribing instructions.
| Research program | What its protocol can show | What it cannot show |
|---|---|---|
| REDEFINE 1 | How researchers tested cagrilintide and semaglutide under supervision | A personal dose or self-directed combination plan |
| RENEW 1 | How once-weekly cagrilintide is studied in a Phase 3 protocol | A routine prescription dose |
| Other studies | Study-specific arms, escalation and outcomes | A schedule assembled from unrelated trials |
What a clinical-trial dose table can show
A trial table can document research doses, escalation periods, control groups and outcomes. It should always identify the study and phase.
What a clinical-trial dose table cannot show
It cannot establish an individual dose, missed-dose rule, storage method or safe combination plan. It also cannot verify the contents of an online vial.
For an existing prescription, follow the approved label and prescriber’s instructions. Patients can also review our guide to compounded semaglutide vial checks.
Online cagrilintide peptides and compounded products
An online listing does not make cagrilintide FDA-approved. “Research use only” does not establish identity, purity, sterility, strength or safety for human use.
Compounded preparations are not FDA-approved products, and compounding does not create approval. Rules depend on the ingredient, facility, prescription and other circumstances.
Why seller test reports are not enough
A seller’s certificate may not correspond to the shipped vial or cover sterility, storage, fill accuracy and chain of custody. Packaging and customer reviews are not substitutes for pharmacy controls.
How to check a lawful prescription source
Use a licensed prescriber and pharmacy. Verify the pharmacy through its state board and resources such as FDA BeSafeRx.
Temi keeps medication and refill details in one place, helping patients verify the exact product rather than relying on a seller’s post.
Cagrilintide price, access, and questions for a prescriber
Our sources do not establish an official commercial list price for cagrilintide. Online peptide prices are not prescription prices.
A clinical trial may provide treatment under its protocol, but participation does not guarantee assignment to the investigational drug or access after the study.
Questions to ask a licensed prescriber
We recommend asking:
- Which approved options fit my diagnosis and medical history?
- What benefits and risks apply to patients like me?
- Which symptoms require medical attention?
- How will treatment and nutrition be monitored?
- What are the total costs, including visits and supplies?
For help identifying an existing prescription, patients can use our prescription refill support.
Questions to ask before joining a trial
Ask who sponsors the trial, whether it uses a placebo or comparator, which costs are covered, how adverse events are handled and what happens after treatment ends.
FAQ
Is cagrilintide better than semaglutide?
Current cross-trial evidence does not prove that it is better. See our cagrilintide versus semaglutide analysis.
What is the difference between cagrilintide and tirzepatide?
Cagrilintide is an amylin analog; tirzepatide targets GIP and GLP-1 receptors. See cagrilintide versus tirzepatide.
What does cagrilintide peptide do?
It is designed to extend amylin-like signaling, but its clinical effects must be established through trials. See how cagrilintide changes the amylin signal.
Who should not take cagrilintide?
There is no FDA-approved contraindication list in our sources. Products labeled for research use should not be taken. See who was excluded from trials.
Can cagrilintide replace or be added to my GLP-1 drug?
Do not stop, replace or combine prescribed medicines based on an online chart. Review the evidence on cagrilintide plus semaglutide with a licensed prescriber.
Is cagrilintide available by prescription?
Our sources do not establish an FDA-approved cagrilintide prescription product as of September 7, 2026. Check the approval section for verification steps.
Review an approved treatment plan
Use a licensed prescriber to review approved weight-management options, current medicines, side effects and refill needs. Do not use research cagrilintide or change a GLP-1 prescription without clinical guidance.
